Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism NR2F2 antagonists(nuclear receptor subfamily 2 group F member 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Discovery | - | 12 Sep 2025 | |
| Cerebrovascular Disorders | Discovery | - | 12 Sep 2025 | |
| Infectious Diseases | Discovery | - | 12 Sep 2025 | |
| Metabolic Diseases | Discovery | - | 12 Sep 2025 | |
| Neoplasms | Discovery | - | 12 Sep 2025 | |
| Other Diseases | Discovery | - | 12 Sep 2025 |





